Literature DB >> 24048610

Antinociceptive effect of intracerebroventricular administration of D-serine on formalin-induced pain.

Miho Ito1, Masanobu Yoshikawa, Kenji Ito, Mitsumasa Matsuda, Xing Lu Jin, Shigeru Takahashi, Hiroyuki Kobayashi, Toshiyasu Suzuki.   

Abstract

PURPOSE: In a previous study using the tail-flick test, we found that intracerebroventricular administration of D-serine, an endogenous co-agonist at the glycine sites of N-methyl-D-aspartate (NMDA) receptors, elicited an antinociceptive effect on thermal nociception. The purpose of the present study was to evaluate the effect of intracerebroventricular administration of D-serine on nociception induced by tissue damage or inflammation using the formalin test.
METHODS: Infusion of drugs into the third ventricle in rat was performed via indwelling cannulae. Drugs were infused at a volume of 10 μl over 2 min, and the infusion cannula was left in place for 2 min before removal. The formalin test was performed 10 min after drug administration.
RESULTS: Intracerebroventricular administration of D-serine significantly and dose-dependently decreased the number of flinches in both the early and late phases in the formalin test. This antinociceptive effect was antagonized by intracerebroventricular administration of L-701,324, a selective antagonist at the glycine sites of NMDA receptors.
CONCLUSION: The present data suggest that activation of NMDA receptors via glycine sites at the supraspinal level induces an antinociceptive effect on both acute and tonic pain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048610     DOI: 10.1007/s00540-013-1708-3

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  28 in total

Review 1.  State-dependent opioid control of pain.

Authors:  Howard Fields
Journal:  Nat Rev Neurosci       Date:  2004-07       Impact factor: 34.870

2.  Morphine analgesia in tail-flick and formalin pain tests is mediated by different neural systems.

Authors:  F V Abbott; R Melzack; C Samuel
Journal:  Exp Neurol       Date:  1982-03       Impact factor: 5.330

3.  A role of periaqueductal grey NMDA receptors in mediating formalin-induced pain in the rat.

Authors:  A L Vaccarino; H R Clemmons; G J Mader; J E Magnusson
Journal:  Neurosci Lett       Date:  1997-10-31       Impact factor: 3.046

Review 4.  Free D-aspartate and D-serine in the mammalian brain and periphery.

Authors:  A Hashimoto; T Oka
Journal:  Prog Neurobiol       Date:  1997-07       Impact factor: 11.685

5.  Impaired motor activity and motor learning function in rat with middle cerebral artery occlusion.

Authors:  Yuchuan Ding; Yandong Zhou; Qin Lai; Jie Li; Hun Park; Fernando G Diaz
Journal:  Behav Brain Res       Date:  2002-04-15       Impact factor: 3.332

6.  Sexual differences in onset of disease and response to exercise in a transgenic model of ALS.

Authors:  J H Veldink; P R Bär; E A J Joosten; M Otten; J H J Wokke; L H van den Berg
Journal:  Neuromuscul Disord       Date:  2003-11       Impact factor: 4.296

7.  Laser-Doppler scanning of local cerebral blood flow and reserve capacity and testing of motor and memory functions in a chronic 2-vessel occlusion model in rats.

Authors:  P T Ulrich; S Kroppenstedt; A Heimann; O Kempski
Journal:  Stroke       Date:  1998-11       Impact factor: 7.914

8.  Apparent lack of tolerance in the formalin test suggests different mechanisms for morphine analgesia in different types of pain.

Authors:  F V Abbott; K B Franklin; R J Ludwick; R Melzack
Journal:  Pharmacol Biochem Behav       Date:  1981-10       Impact factor: 3.533

9.  Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging.

Authors:  A Hashimoto; T Nishikawa; T Oka; K Takahashi
Journal:  J Neurochem       Date:  1993-02       Impact factor: 5.372

10.  Differential modulation of kappa and mu opioid antinociception by the glycine/NMDA receptor agonist D-serine.

Authors:  J C Hunter; P Atwal; G N Woodruff; L Singh
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.